Article

Anatomic pathology eLearning and resources

Resources to support pathologists

The Pathology Lab Global Medical Affairs team is the medical and scientific face of Roche Tissue Diagnostics, collaborating with the broader medical, diagnostic, biotech and patient community. We connect with key thought leaders and stakeholders to generate real world data, provide pragmatic knowledge and education surrounding our high medical value assays and tirelessly work to provide solutions that enable patients access to our diagnostic solutions around the globe.

Online courses

Our dedicated team of in-house pathologists has developed a variety of educational modules.

Explore videos and interactive courses, to aid in the interpretation of our assays.

View now

View education portal

About our anatomic pathology online courses

With new emerging biomarkers and new technologies, the practice of pathology is growing and changing daily. We are committed to providing pathologists with up-to-date information, education and training that will advance your knowledge and elevate your confidence in results. This portal provides the tools you need to explore and understand the newest horizons of pathology, including companion diagnostics, immunotherapy, and biomarker and disease state information. Below, find access to educational modules, cutting-edge research articles, and more.

Featured courses: high medical value assays

VENTANA ALK (D5F3) Assay in non-small cell lung cancer (NSCLC)

VENTANA ALK (D5F3) Assay in non-small cell lung cancer (NSCLC)

A comprehensive interactive training course for the only CE marked Companion Diagnostics ALK IHC binary assay for NSCLC. The course is designed for pathologists and other professional users to provide background, science and interpretation of the VENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody (VENTANA ALK (D5F3) Assay) for use in the evaluation of NSCLC.

Over the sequential four modules, the user will learn how to assess the staining and interpretation of the VENTANA ALK (D5F3) Assay and concludes with a proficiency test. A certificate is offered to those who successfully complete the course.

Course completion time: 2-3 hours. Modules:

Introduction and ALK Basics
Guided demonstration of NSCLC cases with known clinical
Interpretation
Guided demonstration of NSCLC cases with unknown clinical
Interpretation
Practice session of NSCLC cases with unknown clinical interpretation
Proficiency Test

View education portal

HER2 Dual ISH Interpretation Training

HER2 Dual ISH Interpretation Training

This course was designed for pathologists and provides a step-by-step guide on the evaluation and scoring of HER2 Dual ISH staining. Participants are required to proceed through the five-part training program in chronological order.

Modules:

Basics and interpretation
Guided demonstration of cases
Practices cases with assisted interpretation
Stain interpretation practice exam
Stain interpretation exam

View eLearning portal

PD-L1 interpretation training series

PD-L1 interpretation training series

Stay at the forefront of predictive diagnostics and make a positive impact on patient care. This a series of focused, interactive courses was developed to aid the scoring and interpretation of VENTANA PD-L1 (SP142) Assay* and VENTANA PD-L1 (SP263) Assay to target those patients who are more likely to respond to specific therapies.

*CE IVD only. Not for use in diagnostic procedures in the US.

Modules:

PD-L1 Basics Module: This course gives a background in the biology of PD-L1 and a description of the PD-L1 Assays.
PD-L1 (SP142) UC Training: This course consists of five modules that go through the basics to interpret bladder tissue stained with the VENTANA PD-L1 (SP142) Assay, including an interactive assessment test to measure your own interpretation skills.
PD-L1 (SP142) NSCLC Training: This course consists of four modules that go through the basics to interpret lung tissue stained with the VENTANA PD-L1 (SP142) Assay, including an interactive assessment test to measure your own interpretation skills.
PD-L1 (SP142) TNBC Training: This course consists of five modules that go through the basics to interpret breast tissue stained with the VENTANA PD-L1 (SP142) Assay, including an interactive assessment test to measure your own interpretation skills.
PD-L1 (SP263) UC Training: This course consists of nine modules that go through the basics to interpret bladder tissue stained with the VENTANA PD-L1 (SP263) Assay, including an interactive assessment test to measure your own interpretation skills.
PD-L1 (SP263) NSCLC Training: This course consists of six modules that go through the basics to interpret lung tissue stained with the VENTANA PD-L1 (SP263) Assay, including an interactive assessment test to measure your own interpretation skills.

View eLearning portal

DIASights webinar series

This series - brought to you by Roche Diagnostics - features key opinion leaders' insights and curated educational content related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.

DIASights webinar series

Watch the webinar series on the DIASights BrighTALK channel

Explore

Featured webinars

Module 1: Ventana PD-L1 (SP263) NSCLC Assay Overview

Dr. Dorothy Hayden, Pathologist at Roche

Jul 23 2020 | 10 mins

This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).

Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.

These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review.

The Pathologist in the Era of Immunotherapy

Dr. Ken Bloom

Jul 23 2020 | 60 mins

The job of the pathologist is crucial in the era of precision medicine and immunotherapy. Pathologists need not only to correctly diagnose and classify tumors, but also aid in the selection of the best treatment strategies based on the presence or absence of critical biomarkers. Because tumors are heterogeneous, this includes discussion with the interventionalist about which lesions to sample in metastatic disease and selection of the best area of tumor for analysis in resections. While next generation sequencing techniques provide a plethora of data about mutations, gene expression and copy number, the pathologist must interpret these results in the context of the histologic appearance of the sample. In this webinar, Dr. Bloom will review the challenges faced by pathologists today with the emergence of immunotherapy and explain the critical role of the pathologist in assessing the tumor and its microenvironment.

Digital Pathology: Current and Future Benefits Using PD-L1 as the Paradigm

Dr. Alex Haragan, Pathologist MRC Clinical Research Fellow at Royal Liverpool University Hospital, Liverpool, England

Aug 27 2020 | 59 mins

This webinar will give an overview of the Roche uPath software with particular regards to digital slide image viewing and the use of the PD-L1 immunohistochemistry interpretation algorithm. The pros and cons of digital pathology and uPath will be considered, with a focus on the use of the PD-L1 algorithm and how this can be used to augment pathologists' ability to interpret this tricky predictive biomarker in the context of NSCLC.

NTRK gene fusions in solid tumors: IHC and molecular testing strategies

In this webinar Drs. Marchiò and Büttner will review the role of NTRK gene fusions in solid tumors, with an in-depth look at IHC and molecular methods of testing.

...

Please note that not all services and/or products are offered in all countries.